Condition: Advanced Solid Tumors · Hematologic Malignancies · Sponsor: Acrotech Biopharma Inc.
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of every 7-week treatment cycle in patients with hepatic impairment. Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.
This description comes directly from the study's public registry record.
Uma Srinivas Atmuri · 732-917-2420 · uatmuri@acrotechbiopharma.com
Motun Clinical Trial Manager · 617-694-4296 · msolomon@acrotechbiopharma.com
Always discuss trial participation with your own doctor first.
| TOI Clinical Research | Cerritos, California, United States | Withdrawn |
| Northwestern University - Feinberg School of Medicine | Chicago, Illinois, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Gabrail Cancer Center | Canton, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07036133